Targeting Lysosomal Degradation Pathways: New Strategies and Techniques for Drug Discovery. 2021

Junping Pei, and Guan Wang, and Lu Feng, and Jifa Zhang, and Tingting Jiang, and Qiu Sun, and Liang Ouyang
State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, Innovation Center of Nursing Research, Nursing Key Laboratory of Sichuan Province, West China Hospital, and Collaborative Innovation Center of Biotherapy, Sichuan University, Chengdu 610041, China.

A series of tools for targeted protein degradation are inspiring scientists to develop new drugs with advantages over traditional small-molecule drugs. Among these tools, proteolysis-targeting chimeras (PROTACs) are most representative of the technology based on proteasomes. However, the proteasome has little degradation effect on certain macromolecular proteins or aggregates, extracellular proteins, and organelles, which limits the application of PROTACs. Additionally, lysosomes play an important role in protein degradation. Therefore, lysosome-induced protein degradation drugs can directly regulate protein levels in vivo, achieve the goal of treating diseases, and provide new strategies for drug discovery. Lysosome-based degradation technology has the potential for clinical translation. In this review, strategies targeting lysosomal pathways and lysosome-based degradation techniques are summarized. In addition, lysosome-based degrading drugs are described, and the advantages and challenges are listed. Our efforts will certainly promote the design, discovery, and clinical application of drugs associated with this technology.

UI MeSH Term Description Entries
D008247 Lysosomes A class of morphologically heterogeneous cytoplasmic particles in animal and plant tissues characterized by their content of hydrolytic enzymes and the structure-linked latency of these enzymes. The intracellular functions of lysosomes depend on their lytic potential. The single unit membrane of the lysosome acts as a barrier between the enzymes enclosed in the lysosome and the external substrate. The activity of the enzymes contained in lysosomes is limited or nil unless the vesicle in which they are enclosed is ruptured or undergoes MEMBRANE FUSION. (From Rieger et al., Glossary of Genetics: Classical and Molecular, 5th ed). Autolysosome,Autolysosomes,Lysosome
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D004705 Endocytosis Cellular uptake of extracellular materials within membrane-limited vacuoles or microvesicles. ENDOSOMES play a central role in endocytosis. Endocytoses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000071182 Autophagosomes Large spherical double-layered structures which function in AUTOPHAGY to engulf intracellular components such as ORGANELLES or pathogens. Their outer membrane then fuses with the LYSOSOME (forming the AUTOLYSOSOME) and the inner membrane and contents are digested by lysosomal HYDROLASES. Phagophores,Autophagosome,Phagophore
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001343 Autophagy The segregation and degradation of various cytoplasmic constituents via engulfment by MULTIVESICULAR BODIES; VACUOLES; or AUTOPHAGOSOMES and their digestion by LYSOSOMES. It plays an important role in BIOLOGICAL METAMORPHOSIS and in the removal of bone by OSTEOCLASTS. Defective autophagy is associated with various diseases, including NEURODEGENERATIVE DISEASES and cancer. Autophagocytosis,ER-Phagy,Lipophagy,Nucleophagy,Reticulophagy,Ribophagy,Autophagy, Cellular,Cellular Autophagy,ER Phagy
D017527 Receptor, IGF Type 2 A receptor that is specific for IGF-II and mannose-6-phosphate. The receptor is a 250-kDa single chain polypeptide which is unrelated in structure to the type 1 IGF receptor (RECEPTOR, IGF TYPE 1) and does not have a tyrosine kinase domain. IGF Type 2 Receptor,IGF-II Receptor,Receptor, IGF-II,Receptor, Insulin-Like Growth Factor II,Receptor, Insulin-Like Growth Factor Type 2,Receptor, Mannose-6-Phosphate,IGF-2 Receptor,Insulin-Like-Growth-Factor II Receptor,Mannose-6-Phosphate Receptor,Receptors, IGF-2,Receptors, Insulin-Like Growth Factor II,IGF 2 Receptor,IGF II Receptor,IGF-2 Receptors,Insulin Like Growth Factor II Receptor,Mannose 6 Phosphate Receptor,Receptor, IGF II,Receptor, IGF-2,Receptor, Insulin Like Growth Factor II,Receptor, Insulin Like Growth Factor Type 2,Receptor, Insulin-Like-Growth-Factor II,Receptor, Mannose 6 Phosphate,Receptors, IGF 2,Receptors, Insulin Like Growth Factor II

Related Publications

Junping Pei, and Guan Wang, and Lu Feng, and Jifa Zhang, and Tingting Jiang, and Qiu Sun, and Liang Ouyang
November 2004, Drug discovery today,
Junping Pei, and Guan Wang, and Lu Feng, and Jifa Zhang, and Tingting Jiang, and Qiu Sun, and Liang Ouyang
January 2022, Future medicinal chemistry,
Junping Pei, and Guan Wang, and Lu Feng, and Jifa Zhang, and Tingting Jiang, and Qiu Sun, and Liang Ouyang
March 2013, Chinese journal of cancer,
Junping Pei, and Guan Wang, and Lu Feng, and Jifa Zhang, and Tingting Jiang, and Qiu Sun, and Liang Ouyang
April 2023, Pharmaceuticals (Basel, Switzerland),
Junping Pei, and Guan Wang, and Lu Feng, and Jifa Zhang, and Tingting Jiang, and Qiu Sun, and Liang Ouyang
January 2015, Current pharmaceutical design,
Junping Pei, and Guan Wang, and Lu Feng, and Jifa Zhang, and Tingting Jiang, and Qiu Sun, and Liang Ouyang
January 2024, International journal of molecular sciences,
Junping Pei, and Guan Wang, and Lu Feng, and Jifa Zhang, and Tingting Jiang, and Qiu Sun, and Liang Ouyang
January 2013, Current chemical genomics and translational medicine,
Junping Pei, and Guan Wang, and Lu Feng, and Jifa Zhang, and Tingting Jiang, and Qiu Sun, and Liang Ouyang
June 2023, Journal of medicinal chemistry,
Junping Pei, and Guan Wang, and Lu Feng, and Jifa Zhang, and Tingting Jiang, and Qiu Sun, and Liang Ouyang
January 2006, Methods in molecular biology (Clifton, N.J.),
Junping Pei, and Guan Wang, and Lu Feng, and Jifa Zhang, and Tingting Jiang, and Qiu Sun, and Liang Ouyang
October 2007, Journal of cellular biochemistry,
Copied contents to your clipboard!